RESEARCH TRIANGLE PARK, N.C., Oct. 2 /PRNewswire-FirstCall/ --
Paradigm Genetics, Inc. (Nasdaq: PDGM), a life sciences company, today
announced the company will host a webcast on October 4, 2002, to provide an
overview of its revised corporate strategy.
DATE: Friday, October 4, 2002
TIME: 8:30 a.m. Eastern Time
INTERNET: http://www.paradigmgenetics.com
SPEAKER: Heiri Gugger, Ph.D., President and CEO
John Hamer, Ph.D., Chief Scientific Officer
About Paradigm Genetics
Paradigm Genetics, Inc., headquartered in Research Triangle Park, NC, is a
life sciences company using genomics and metabolomics-based technologies to
speed the discovery of products for agriculture and human health. In
agriculture, Paradigm has unlocked the potential of functional genomics
through its GeneFunction Factory(TM) industrialized technology platform, which
links gene expression profiling, biochemical profiling, and phenotypic
profiling to create industry-leading genomic knowledge and intellectual
property advantages. Also, Paradigm offers plant breeders genotyping,
molecular breeding and genomic services to accelerate product development
through its business unit ParaGen. In human health, Paradigm partners with
pharmaceutical and other biotechnology companies to transform drug discovery
and development by significantly enhancing the study of drug targets, lead
compounds, and predictive medicine. The company's proprietary MetaVantage(TM)
metabolomics platform elucidates the metabolic profile of a cell, tissue, or
fluid, and integrates this information with data from other genomics analyses
using its proprietary comprehensive informatics system. For more information,
visit http://www.paradigmgenetics.com.
This press release contains forward-looking statements, including
statements regarding Paradigm's ability to use technologies to speed the
discovery of products for agriculture and human health; the prospects of
Paradigm and its partners to market their technologies and develop products;
Paradigm's ability to meet or exceed the expectations of its partners and
customers; as well as Paradigm's prospects for growth and innovation. Such
forward-looking statements are based on management's current expectations and
are subject to a number of risks, factors and uncertainties that may cause
actual results, events and performance to differ materially from those
referred to in the forward-looking statements. These risks, factors and
uncertainties include, but are not limited to, Paradigm's early stage of
development, history of net losses, technological and product development
uncertainties, reliance on research collaborations, uncertainty of additional
funding and ability to protect its patents and proprietary rights. Certain of
these and other risks are identified in Paradigm's annual report on Form 10-K
for the year ended December 31, 2001 and in its quarterly report on Form 10-Q
for the quarter ended June 30, 2002, each filed with the Securities and
Exchange Commission. The Company does not intend to update any of the
forward-looking statements after the date of this release to conform these
statements to actual results or to changes in our expectations, except as may
be required by law.
GeneFunction Factory(TM) and MetaVantage(TM) are U.S. trademarks of
Paradigm Genetics, Inc.
SOURCE Paradigm Genetics, Inc.
 back to top
Related links:
http://www.paradigmgenetics.com
CONTACT:
Melissa Matson, Manager, Corporate
Communications of Paradigm Genetics, Inc., +1-919-425-3000, or
Amy Garay of Noonan Russo Presence Euro RSCG, +1-212-845-4200,
for Paradigm Genetics, Inc.
|
